Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Vanda Pharmaceuticals Inc.’s VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor, has been awarded ...

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) Friday announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide ...

If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative. A replay of the presentation will be available on the Company's ...

Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red ...

Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of ...

Two researchers from Huntsman Cancer Institute at the University of Utah (the U) have discovered a gene variant found in high ...

Pelabresib is a small molecule commercialized by Novartis, with a leading Phase III program in Myelofibrosis. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, ...

Dear Dr. Roach: I read your recent column on shingles. I am 66 years old and in fairly good health. I had both Shingrix shots ...